R-CHOP therapy for MALT lymphoma of the rectum
Dai Chihara
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYoshitoyo Kagami
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasuhiro Oki
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorHarumi Kato
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorHiroshi Onoda
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorShouji Ine
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorHirofumi Taji
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorKazuhito Yamamoto
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasuo Morishima
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorDai Chihara
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYoshitoyo Kagami
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasuhiro Oki
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorHarumi Kato
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorHiroshi Onoda
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorShouji Ine
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorHirofumi Taji
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorKazuhito Yamamoto
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this authorYasuo Morishima
Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
Search for more papers by this author
References
- 1 Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, Felman P, Coiffier B. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997; 15: 1624–30.
- 2
Isaacson P,
Wright DH.
Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma.
Cancer
1983; 52: 1410–6.
10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 3 Yamashita H, Nakagawa K, Asari T, Murakami N, Igaki H, Ohtomo K. Radiotherapy for 41 patients with stages I and II MALT lymphoma: a retrospective study. Radiother Oncol 2008; 87: 412–7.
- 4 Aviles A, Nambo MJ, Neri N, Talavera A, Cleto S. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 2005; 22: 57–62.
- 5 Tsang RW, Gospodarowicz MK, Pintilie M, Wells W, Hodgson DC, Sun A, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157–64.
- 6 Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998; 338: 804–10.
- 7 Montalban C, Santon A, Boixeda D, Redondo C, Alvarez I, Calleja JL, et al. Treatment of low grade gastric mucosa-associated lymphoid tissue lymphoma in stage I with Helicobacter pylori eradication. Long-term results after sequential histologic and molecular follow-up. Haematologica 2001; 86: 609–17.
- 8 Savio A, Zamboni G, Capelli P, Negrini R, Santandrea G, Scarpa A, et al. Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication: true relapse or persistence? Long-term post-treatment follow-up of a multicenter trial in the north-east of Italy and evaluation of the diagnostic protocol’s adequacy. Recent Results Cancer Res 2000; 156: 116–24.
- 9 Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R. Infectious agents in mucosa-associated lymphoid tissue-type lymphomas: pathogenic role and therapeutic perspectives. Clin Lymphoma Myeloma 2006; 6: 289–300.
- 10 Matsumoto T, Iida M, Shimizu M. Regression of mucosa-associated lymphoid-tissue lymphoma of rectum after eradication of Helicobacter pylori. Lancet 1997; 350: 115–6.
- 11 Grunberger B, Wohrer S, Streubel B, Formanek M, Petkov V, Puespoek A, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol 2006; 24: 1370–5.
- 12 Thieblemont C, Berger F, Dumontet C, Moullet I, Bouafia F, Felman P, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95: 802–6.
- 13 Koch P, Del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma – results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001; 19: 3874–83.
- 14 Raderer M, Wohrer S, Streubel B, Drach J, Jager U, Turetschek K, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006; 70: 411–7.
- 15 Wohrer S, Drach J, Hejna M, Scheithauer W, Dirisamer A, Puspok A, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann Oncol 2003; 14: 1758–61.
- 16 Conconi A, Martinelli G, Thieblemont C, Ferreri AJ, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 2741–5.
- 17 Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol 2009; 145: 741–8.
- 18 Orciuolo E, Buda G, Sordi E, Barate C, Galimberti S, Ciancia E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res 2009; [Epub ahead of print].
- 19 Manoharan A. Sustained remissions with long-term weekly chlorambucil maintenance therapy in patients with mucosa-associated lymphoid tissue lymphoma. Int J Hematol 2004; 79: 472–3.
- 20 Hancock BW, Qian W, Linch D, Delchier JC, Smith P, Jakupovic I, et al. Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial. Br J Haematol 2009; 144: 367–75.
- 21 Troch M, Jonak C, Mullauer L, Puspok A, Formanek M, Hauff W, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica 2009; 94: 738–42.
Citing Literature
